Zydus Lifesciences Limited has achieved a significant milestone with the tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, in 40 mg and 80 mg dosages. This medication is an angiotensin II receptor blocker (ARB) specifically used for the treatment of hypertension to lower blood pressure, thereby reducing […]
Beetroot, scientifically known as Beta vulgaris, is a root vegetable known for its deep red color and a multitude of health benefits. Commonly referred to as garden beet, table beet, or red beet, this vegetable is cultivated widely across Central America, North America, and Britain, thriving underground like many other root crops. Culinary Uses and […]
ŌURA, renowned for its Oura Ring smart wearable, has announced the introduction of two innovative heart health features, Cardiovascular Age (CVA) and Cardio Capacity, marking a significant advancement in its product lineup. These features, set to launch in late May 2024, are designed to extend ŌURA’s capabilities from a top-tier sleep tracker to a holistic […]
In a significant development for cardiovascular disease treatment, Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, has presented positive results from its Phase 2 proof-of-concept clinical trial, CARDINAL-HF. This trial tested CRD-740, a phosphodiesterase-9 (PDE9) inhibitor, showcasing its potential to become a new standard of care in heart failure therapy. These findings were revealed at the […]
In a significant advancement for heart health management, Esperion (NASDAQ: ESPR) has announced that the United States Food and Drug Administration (FDA) has approved comprehensive label expansions for its flagship products, NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets. This approval, rooted in the positive data from the CLEAR Outcomes trial, heralds […]
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]
Boston Scientific has announced that its LUMINIZE Radiofrequency (RF) Balloon Catheter, developed for isolating pulmonary veins (PVs) in atrial fibrillation (AF) treatment, has demonstrated positive safety and efficacy results in the AF-FICIENT I clinical trial. This new device marks an advancement in cardiac ablation technology and its ability to enhance treatment outcomes for patients with […]